Endocarditis Caused by Nontypeable Streptococcus pneumoniae.
Streptococcus pneumoniae
bacterial polysaccharide capsule
infective endocarditis
pathogenesis
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
10 09 2022
10 09 2022
Historique:
received:
14
10
2021
pubmed:
9
2
2022
medline:
14
9
2022
entrez:
8
2
2022
Statut:
ppublish
Résumé
The Streptococcus pneumoniae capsule is regarded as indispensable in bacteremia. We report an infant with a ventricular septal defect and infective endocarditis caused by nontypeable S. pneumoniae. In-depth investigation confirmed a deficient capsule yet favored pneumococcal fitness for causing infective endocarditis, rather than a host immune disorder, as the cause of infective endocarditis in this case.
Identifiants
pubmed: 35134152
pii: 6520531
doi: 10.1093/cid/ciac079
pmc: PMC9464071
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
719-722Informations de copyright
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. N. M. v. S. reports that patent WO 2013/020090 A3 has been licensed by the company Vaxcyte, generating royalties when milestones are reached and royalties from a patent on vaccine development against Streptococcus pyogenes, not part of the work submitted here (licensee University of California San Diego inventors, N. M. v. S. and Victor Nizet). N. M. v. S. also reports consulting fees from MSD (fee for service paid directly to the institution, related to pneumococcal invasive disease, and consulting fee for an expert panel) and GlaxoSmithKline (fee for service paid directly to the institution, related to pneumococcal invasive disease); payment or honoraria from MSD for expert meeting contribution on pneumococcal disease); and personal stocks from GenMab, Bank of America, and exchange-traded funds. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
FEMS Microbiol Lett. 2014 May;354(1):46-54
pubmed: 24654559
Clin Microbiol Rev. 2015 Jul;28(3):871-99
pubmed: 26085553
Mol Oral Microbiol. 2012 Aug;27(4):246-56
pubmed: 22759310
Circulation. 2020 Aug 25;142(8):720-730
pubmed: 32580572
Clin Microbiol Rev. 2004 Jan;17(1):218-34
pubmed: 14726462
Medicine (Baltimore). 2015 Sep;94(39):e1562
pubmed: 26426629
PLoS Genet. 2006 Mar;2(3):e31
pubmed: 16532061
Clin Infect Dis. 2017 Jun 15;64(suppl_3):S368-S377
pubmed: 28575366
J Infect Dis. 1992 Apr;165(4):749-53
pubmed: 1552206
PLoS One. 2016 Jul 19;11(7):e0159558
pubmed: 27433935
Nat Rev Dis Primers. 2016 Sep 01;2:16059
pubmed: 27582414
PLoS One. 2014 May 15;9(5):e97825
pubmed: 24831650
Medicine (Baltimore). 2003 Sep;82(5):322-32
pubmed: 14530781
mBio. 2016 Mar 22;7(2):e01792
pubmed: 27006456
Nat Commun. 2014 Sep 30;5:5055
pubmed: 25268848